Estrogenicity of essential oils is not required to relieve symptoms of urogenital atrophy in breast cancer survivorsCitation formats

  • External authors:
  • Bertram Kholer
  • Jacqui Stringer
  • Lily Novak Frazer
  • Keely Young
  • Giorgia Zucchini
  • Anne Armstrong

Standard

Estrogenicity of essential oils is not required to relieve symptoms of urogenital atrophy in breast cancer survivors. / M Simoes, Bruno; Kholer, Bertram ; Clarke, Robert; Stringer, Jacqui; Novak Frazer, Lily; Young, Keely ; Richardson, Riina; Zucchini, Giorgia; Armstrong, Anne; Howell, Sacha.

In: Therapeutic Advances in Medical Oncology, Vol. 10, 2018.

Research output: Contribution to journalArticle

Harvard

M Simoes, B, Kholer, B, Clarke, R, Stringer, J, Novak Frazer, L, Young, K, Richardson, R, Zucchini, G, Armstrong, A & Howell, S 2018, 'Estrogenicity of essential oils is not required to relieve symptoms of urogenital atrophy in breast cancer survivors' Therapeutic Advances in Medical Oncology, vol. 10. https://doi.org/10.1177/1758835918766189

APA

Vancouver

Author

M Simoes, Bruno ; Kholer, Bertram ; Clarke, Robert ; Stringer, Jacqui ; Novak Frazer, Lily ; Young, Keely ; Richardson, Riina ; Zucchini, Giorgia ; Armstrong, Anne ; Howell, Sacha. / Estrogenicity of essential oils is not required to relieve symptoms of urogenital atrophy in breast cancer survivors. In: Therapeutic Advances in Medical Oncology. 2018 ; Vol. 10.

Bibtex

@article{b8f2e022013d4571ac41f38e554a1f26,
title = "Estrogenicity of essential oils is not required to relieve symptoms of urogenital atrophy in breast cancer survivors",
abstract = "Background: Urogenital atrophy (UA) is a common treatment-limiting side effect of endocrine therapies. Topical estrogen is effective but systemic absorption may counter aromatase inhibitor efficacy. Numerous complementary approaches are marketed for use in UA without rigorous testing of their estrogenicity. We tested multiple essential oils in cancer cell growth and estrogen reporter assays in vitro and assessed clinical outcomes with the essential oil pessaries (EOP) in breast cancer survivors with UA.Methods: Effects on cell growth were tested in hormone dependent (MCF-7) and independent (MDA-MB-231) cell lines using the sulforhodamine-B assay. An estrogenic response element (ERE) luciferase reporter assay was used to assess estrogenicity directly. Antifungal activity against two common pathogenic yeasts was assessed using standard microdilution methods. EOPs were offered to breast cancer survivors with symptomatic UA and the service evaluated using serial questionnaires.Results: Two essential oils, Cymbopogon martinii and Pelargonium graveolens, demonstrated marked estrogenicity, stimulating ER+ cell growth and ERE-luciferase reporter activity to levels seen with premenopausal estradiol concentrations. Additional oils were screened for estrogenicity and Lavandula angustifolia and Chamaemelum nobile identified as non/minimally estrogenic. The antifungal activity of this combination of oils was confirmed. A second cohort of breast cancer survivors with UA received the second generation EOP with comparable improvement in symptom scores suggesting that estrogenicity may not be required for optimal therapy of UA. Conclusion: Certain essential oils demonstrate profound estrogenicity and caution should be exercised before their use in breast cancer survivors. Our minimally estrogenic pessary will be formally tested in clinical trials.",
author = "{M Simoes}, Bruno and Bertram Kholer and Robert Clarke and Jacqui Stringer and {Novak Frazer}, Lily and Keely Young and Riina Richardson and Giorgia Zucchini and Anne Armstrong and Sacha Howell",
year = "2018",
doi = "10.1177/1758835918766189",
language = "English",
volume = "10",
journal = "Therapeutic Advances in Medical Oncology",
issn = "1758-8340",
publisher = "Sage Publications Ltd.",

}

RIS

TY - JOUR

T1 - Estrogenicity of essential oils is not required to relieve symptoms of urogenital atrophy in breast cancer survivors

AU - M Simoes, Bruno

AU - Kholer, Bertram

AU - Clarke, Robert

AU - Stringer, Jacqui

AU - Novak Frazer, Lily

AU - Young, Keely

AU - Richardson, Riina

AU - Zucchini, Giorgia

AU - Armstrong, Anne

AU - Howell, Sacha

PY - 2018

Y1 - 2018

N2 - Background: Urogenital atrophy (UA) is a common treatment-limiting side effect of endocrine therapies. Topical estrogen is effective but systemic absorption may counter aromatase inhibitor efficacy. Numerous complementary approaches are marketed for use in UA without rigorous testing of their estrogenicity. We tested multiple essential oils in cancer cell growth and estrogen reporter assays in vitro and assessed clinical outcomes with the essential oil pessaries (EOP) in breast cancer survivors with UA.Methods: Effects on cell growth were tested in hormone dependent (MCF-7) and independent (MDA-MB-231) cell lines using the sulforhodamine-B assay. An estrogenic response element (ERE) luciferase reporter assay was used to assess estrogenicity directly. Antifungal activity against two common pathogenic yeasts was assessed using standard microdilution methods. EOPs were offered to breast cancer survivors with symptomatic UA and the service evaluated using serial questionnaires.Results: Two essential oils, Cymbopogon martinii and Pelargonium graveolens, demonstrated marked estrogenicity, stimulating ER+ cell growth and ERE-luciferase reporter activity to levels seen with premenopausal estradiol concentrations. Additional oils were screened for estrogenicity and Lavandula angustifolia and Chamaemelum nobile identified as non/minimally estrogenic. The antifungal activity of this combination of oils was confirmed. A second cohort of breast cancer survivors with UA received the second generation EOP with comparable improvement in symptom scores suggesting that estrogenicity may not be required for optimal therapy of UA. Conclusion: Certain essential oils demonstrate profound estrogenicity and caution should be exercised before their use in breast cancer survivors. Our minimally estrogenic pessary will be formally tested in clinical trials.

AB - Background: Urogenital atrophy (UA) is a common treatment-limiting side effect of endocrine therapies. Topical estrogen is effective but systemic absorption may counter aromatase inhibitor efficacy. Numerous complementary approaches are marketed for use in UA without rigorous testing of their estrogenicity. We tested multiple essential oils in cancer cell growth and estrogen reporter assays in vitro and assessed clinical outcomes with the essential oil pessaries (EOP) in breast cancer survivors with UA.Methods: Effects on cell growth were tested in hormone dependent (MCF-7) and independent (MDA-MB-231) cell lines using the sulforhodamine-B assay. An estrogenic response element (ERE) luciferase reporter assay was used to assess estrogenicity directly. Antifungal activity against two common pathogenic yeasts was assessed using standard microdilution methods. EOPs were offered to breast cancer survivors with symptomatic UA and the service evaluated using serial questionnaires.Results: Two essential oils, Cymbopogon martinii and Pelargonium graveolens, demonstrated marked estrogenicity, stimulating ER+ cell growth and ERE-luciferase reporter activity to levels seen with premenopausal estradiol concentrations. Additional oils were screened for estrogenicity and Lavandula angustifolia and Chamaemelum nobile identified as non/minimally estrogenic. The antifungal activity of this combination of oils was confirmed. A second cohort of breast cancer survivors with UA received the second generation EOP with comparable improvement in symptom scores suggesting that estrogenicity may not be required for optimal therapy of UA. Conclusion: Certain essential oils demonstrate profound estrogenicity and caution should be exercised before their use in breast cancer survivors. Our minimally estrogenic pessary will be formally tested in clinical trials.

U2 - 10.1177/1758835918766189

DO - 10.1177/1758835918766189

M3 - Article

VL - 10

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

SN - 1758-8340

ER -